Risperidone Microspheres
Brand names: Risperdal Consta, Risperidone Er
Part of: Antipsychotics
At a glance
- Medicare prescriptions, 2024
- 84,298
- Medicare drug cost
- $108.6M
- Average cost per prescription
- $1,288
- Clinicians who prescribed it
- 3,419
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
RISPERDAL CONSTA is an atypical antipsychotic indicated: for the treatment of schizophrenia. as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder. 1.1 Schizophrenia RISPERDAL CONSTA (risperidone)
From the FDA-approved prescribing information (label dated November 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL CONSTA is not approved for the treatment of patients with dementia-related psychosis.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 37.0%
- Psychiatric Nurse Practitioners 27.9%
- Nurse Practitioners 9.3%
- Internal Medicine 8.8%
- Family Medicine 8.1%
- Physician Assistants 2.9%
- Child & Adolescent Psychiatry 2.0%
- Geriatric Medicine 1.4%
- General Practice 0.7%
- Emergency Medicine 0.4%
- Neurology 0.3%
- Hospitalist 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 41% from 2019 to 2024.
Biggest change by state since 2019
- New York −27%
- Minnesota −31%
- Georgia −31%
- New Jersey −33%
- Texas −36%
- Arizona (smallest change) −58%
- Illinois (smallest change) −50%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.